Mathew Tilson
Nurse Practitioner · Milwaukee, WINPI 1467763813
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,625 of the $20,762 with a category attached, or 84.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 976 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- AbbVie$4K
- AstraZeneca$1K
- Pfizer$990
- Novo Nordisk$839
- Takeda Pharmaceuticals U.S.A., Inc.$803
- plus $8K from 54 others
What the payments were for
- Consulting fees$1,8309%
- Travel & lodging$1,1285%
- Food & beverage$17,62585%
- Education$1791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,762 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 178 | $193,491 |
| JardianceEmpagliflozin | 147 | $135,688 |
| IngrezzaValbenazine Tosylate | 13 | $101,277 |
| LinzessLinaclotide | 154 | $99,910 |
| EliquisApixaban | 136 | $94,927 |
| VraylarCariprazine Hcl | 47 | $73,180 |
| OzempicSemaglutide | 39 | $49,265 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $44,136 |
| TrulicityDulaglutide | 37 | $38,005 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $26,398 |
| FarxigaDapagliflozin Propanediol | 30 | $26,252 |
| Fondaparinux Sodium | 12 | $18,896 |
| WegovySemaglutide | 11 | $14,601 |
| XareltoRivaroxaban | 19 | $14,333 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 112 | $12,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $780 | $231,497215 claims |
| AbbVieLinzess, Vraylar | $3,626 | $173,090201 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $485 | $157,426188 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $107 | $101,27713 claims |
| PfizerEliquis | $990 | $94,927136 claims |
| Novo NordiskOzempic, Wegovy | $839 | $63,86650 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,411 | $52,65071 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $313 | $51,05685 claims |
| Johnson & JohnsonXarelto | $771 | $14,33319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $803 | $12,55822 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $66 | $11,66018 claims |
| BayerKerendia | $528 | $10,76517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.
Other nurse practitioner in Milwaukee
- Trisha WilcoxMilwaukee$174K
- Christina SauldMilwaukee$111K
- Kelly FlugaurMilwaukee$38K
- Mary Elizabeth Nelson-BiersachMilwaukee$18K
- Angela KrausMilwaukee$17K
- Megan LaneMilwaukee$14K
- Heather SandersMilwaukee$13K
- Cindy KoplitzMilwaukee$12K
- Cheryl BlaschukMilwaukee$10K
- Ashley TaylorMilwaukee$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.